Oxolife, a biotech company, raises 5 million euros for its Phase II Clinical Trial. Inveready leads the investment round together with CDTI, BStartup and HighStick, among other investors

by Inveready Asset Management

The biotech company Oxolife, created to develop a new treatment to improve the female fertility rate, completed its first funding round by raising 5,000,000 euros in an investment led by Inveready Ass...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Diana Capital Acquires a 46% Stake in Au...

by Diana Capital

Aurora Intelligent Nutrition has established itself as one of Europe's...

Photos Stream